Severe gastrointestinal mucositis following high dose melphalan therapy for multiple myeloma

被引：2
|
作者：
Sharma, Sanjeev Kumar [1 ]
Handoo, Anil [1 ]
Choudhary, Dharma [1 ]
Dhamija, Gaurav [1 ]
Gupta, Nitin [1 ]
机构：
[1] BLK Superspecial Hosp, Dept Hematooncol & Bone Marrow Transplant, New Delhi 110005, India
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2013年 / 19卷 / 05期
关键词：
Gastrointestinal mucositis; Chemotherapy; RISK-FACTORS;
D O I：
10.3748/wjg.v19.i5.784
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mucositis is a known complication following use of chemotherapy, but fatal mucositis is unusual and management of such cases may be challenging. Pathologically there is denudation of mucosa of gastrointestinal tract. Severe cases can develop ileus and even perforation of bowel wall. We report here a case of multiple myeloma who developed World Health Organization grade 4 gut mucositis following the use of high dose melphalan with the expulsion of "intestine-like" material. (C) 2013 Baishideng. All rights reserved.
引用
收藏
页码：784 / 785
页数：2
相关论文
共 50 条
  • [31] Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa
    Marcussen, Mette
    Bodker, Julie Stove
    Christensen, Heidi Sogaard
    Johansen, Preben
    Nielsen, Soren
    Christiansen, Ilse
    Bergmann, Olav Jonas
    Bogsted, Martin
    Dybkaer, Karen
    Vyberg, Mogens
    Johnsen, Hans Erik
    PLOS ONE, 2017, 12 (01):
  • [32] Amifostine can reduce oral mucositis after high-dose melphalan conditioning in patients with multiple myeloma: A retrospective study.
    Italiano, A
    Chamorey, E
    Foa, C
    Peyrade, F
    Otto, J
    Thyss, A
    BLOOD, 2004, 104 (11) : 338B - 338B
  • [33] Cryotherapy Reduces Mucositis in Multiple Myeloma Patients Receiving High-Dose Melphalan Conditioning Prior to Autologous Stem Cell Transplantation
    Rodriguez, Mabel
    Adel, Nelly G.
    Devlin, Sean
    Giralt, Sergio A.
    Landau, Heather
    BLOOD, 2012, 120 (21)
  • [34] THE ROLE OF THALIDOMIDE MAINTENANCE FOLLOWING HIGH DOSE THERAPY IN PATIENTS WITH MULTIPLE MYELOMA
    Bila, J.
    Lekovic, D.
    Smiljanic, M.
    Sretenovic, A.
    Vujic, D.
    Veljkovic, D.
    Antic, D.
    Sefer, D.
    Kraguljac, N.
    Andjelic, B.
    Todorovic, M.
    Elezovic, I.
    Tomin, D.
    Gotic, M.
    Mihaljevic, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 391 - 392
  • [35] IDIOTYPIC IMMUNOGLOBULIN AS AN INDICATOR OF RESIDUAL DISEASE IN MULTIPLE-MYELOMA FOLLOWING TREATMENT WITH HIGH-DOSE MELPHALAN
    THOMPSON, J
    SELBY, P
    ANDERSON, V
    MCELWAIN, TJ
    STEVENSON, GT
    BRITISH JOURNAL OF CANCER, 1987, 55 (03) : 345 - 345
  • [36] High-dose therapy in multiple myeloma
    Harousseau, JL
    ANNALS OF ONCOLOGY, 2002, 13 : 49 - 54
  • [37] High-dose therapy in multiple myeloma
    Dimopoulos, MA
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 142 - 143
  • [38] High dose therapy in multiple myeloma -: Discussion
    Binet, JL
    Euzéby, J
    Caen, J
    Paolaggi, JP
    Godeau, P
    Queneau, P
    Guénot, M
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2003, 187 (02): : 413 - 415
  • [39] HIGH-RISK MULTIPLE-MYELOMA TREATED WITH HIGH-DOSE MELPHALAN
    LOKHORST, HM
    MEUWISSEN, OJAT
    VERDONCK, LF
    DEKKER, AW
    JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) : 47 - 51
  • [40] Prospective oral mucositis audit (POMA):: Occurrence and consequences of severe oral mucositis in high dose melphalan and BEAM conditioning.
    Blijlevens, Nicole N. A.
    McCann, Shaun
    Bacon, Pam
    Cinneide, Roisin
    Quinn, Barry
    Roosaar, Ann
    Schouten, Harry
    Schwenkglenks, Matthias
    Stone, Rebecca
    BLOOD, 2006, 108 (11) : 18A - 19A
12345